Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 91 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

5%

5 trials in Phase 3/4

Results Transparency

50%

5 of 10 completed with results

Key Signals

5 with results100% success

Data Visualizations

Phase Distribution

69Total
Not Applicable (38)
Early P 1 (1)
P 1 (7)
P 2 (18)
P 3 (4)
P 4 (1)

Trial Status

Recruiting56
Active Not Recruiting13
Completed10
Not Yet Recruiting6
Enrolling By Invitation4
Suspended1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (91)

Showing 20 of 20 trials
NCT06357988Phase 2Active Not Recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

NCT04829136Not ApplicableRecruitingPrimary

Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies

NCT06945380Not ApplicableRecruiting

Evaluating a Mobile Health Application Intervention for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy

NCT06513962Phase 3RecruitingPrimary

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

NCT06565260Not ApplicableRecruitingPrimary

Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors

NCT05490771Phase 2Active Not Recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

NCT04320888Phase 2Active Not RecruitingPrimary

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04387656Active Not Recruiting

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT07141407Not ApplicableRecruiting

Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person

NCT07052630Not ApplicableRecruitingPrimary

Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial

NCT07535008Not ApplicableRecruiting

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NCT07545291Not ApplicableNot Yet RecruitingPrimary

A Spiritual Health Intervention (PATH) for Improving Spiritual, Religious and Emotional Distress in Cancer Patients

NCT07216534Not ApplicableRecruitingPrimary

Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants

NCT07025538Phase 1RecruitingPrimary

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT07336238Phase 2Recruiting

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

NCT07215039Enrolling By InvitationPrimary

Improving Prison Health Equity Through Cancer Literacy and Screening Awareness in Florida

NCT07349771Phase 2Not Yet RecruitingPrimary

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT06009926Phase 2Active Not RecruitingPrimary

Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters

NCT06198010Not ApplicableRecruiting

A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors

NCT05691491Phase 1Recruiting

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Scroll to load more

Research Network

Activity Timeline